{"disease":{"id":"adenocarcinoma-gastroesophageal-junction-gej","name":"adenocarcinoma gastroesophageal junction gej"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03504397","title":"A Study to Compare Zolbetuximab (IMAB362) and Chemotherapy With Placebo and Chemotherapy in Adults With Gastric Cancer.","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":565,"lead_sponsor_name":"Astellas Pharma Global Development, Inc.","has_results":true},{"nct_id":"NCT03653507","title":"A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW).","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":507,"lead_sponsor_name":"Astellas Pharma Global Development, Inc.","has_results":true},{"nct_id":"NCT06901531","title":"A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Astellas Pharma Global Development, Inc.","has_results":false},{"nct_id":"NCT05365581","title":"A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":398,"lead_sponsor_name":"Astellas Pharma Global Development, Inc.","has_results":false},{"nct_id":"NCT06902545","title":"A Study to Observe the Safety of VYLOY (Zolbetuximab) in People in South Korea With Gastric or Gastroesophageal Junction Cancer.","phase":"","overall_status":"RECRUITING","enrollment_count":377,"lead_sponsor_name":"Astellas Pharma Korea, Inc.","has_results":false},{"nct_id":"NCT07260461","title":"The Efficacy and Safety of Laparoscopic Proximal Gastrectomy With LPG-tbROSF Versus LTG for Localized Proximal Gastric Cancer.","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":120,"lead_sponsor_name":"First Affiliated Hospital of Wenzhou Medical University","has_results":false},{"nct_id":"NCT07359443","title":"Combination of Chemotherapy and Adaptive MR-Guided Radiotherapy to Improve Outcomes in Patients With Esophageal Adenocarcinoma","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":39,"lead_sponsor_name":"UMC Utrecht","has_results":false},{"nct_id":"NCT06299163","title":"NM32-2668 in Adult Patients With Selected Advanced Solid Tumors","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":11,"lead_sponsor_name":"Numab Therapeutics AG","has_results":false},{"nct_id":"NCT06048081","title":"Early Access Program for Zolbetuximab","phase":"","overall_status":"AVAILABLE","enrollment_count":null,"lead_sponsor_name":"Astellas Pharma Global Development, Inc.","has_results":false}],"total":9},"guidelines":[],"source":"Drug Landscape verified database"}